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ABSTRACT We have studied the actin-activated ATPase activities of three mutations in the motor domain of the myosin
heavy chain that cause familial hypertrophic cardiomyopathy. We placed these mutations in rodent -cardiac myosin to
establish the relevance of using rodent systems for studying the biochemical mechanisms of the human disease. We also
wished to determine whether the biochemical defects in these mutant alleles correlate with the severity of the clinical
phenotype of patients with these alleles. We expressed histidine-tagged rat cardiac myosin motor domains along with rat
ventricular light chain 1 in mammalian COS cells. Those myosins studied were wild-type -cardiac and three mutations in the
-cardiac myosin heavy chain head (Arg249Gln, Arg403Gln, and Val606Met). These mutations in human -cardiac myosin
heavy chain have predominantly moderate, severe, and mild clinical phenotypes, respectively. The crystal structure of the
skeletal myosin head shows that the Arg249Gln mutation is near the ATP-binding site and the Arg403Gln and Val606Met
mutations are in the actin-binding region. Expressed histidine-tagged -motor domains retain physiological ATPase prop-
erties similar to those derived from cardiac tissue. All three myosin mutants show defects in the ATPase activity, with the
degree of enzymatic impairment of the mutant myosins correlated with the clinical phenotype of patients with the disease
caused by the corresponding mutation.
INTRODUCTION
Familial hypertrophic cardiomyopathy (FHC) is an autoso-
mal dominant cardiac disease characterized by asymmetri-
cal interventricular and left ventricular hypertrophy and
myocellular disarray (Davies, 1984; Maron et al., 1987).
The disease is clinically variable, ranging from benign to
severe, and often results in sudden death in young athletes
(Maron et al., 1978, 1986). FHC is also genetically hetero-
geneous, because it is caused by multiple mutations in at
least seven different genes (Solomon et al., 1990; Dausse
and Schwartz, 1993; Watkins et al., 1995c). All mutations
found to cause FHC are structural proteins of the sarcomere:
-myosin heavy chain (MyHC) (Geisterfer-Lowrance et al.,
1990; Watkins et al., 1993), -tropomyosin (Watkins et al.,
1995b), troponin T (Thierfelder et al., 1994), myosin bind-
ing protein-C (Watkins et al., 1995a; Bonne et al., 1995),
ventricular light chains, light chain 1 (VLC1) and ventric-
ular light chain 2 (VLC2) (Poetter et al., 1996), and troponin
I (Kimura et al., 1997). The fact that all FHC-causing genes
thus far identified are structural proteins suggests that FHC
is a disease of the sarcomere (Thierfelder et al., 1994).
Over 40 different MyHC alleles have been described
(reviewed in Vikstrom and Leinwand, 1996). These muta-
tions account for30% of the reported FHC cases (Watkins
et al., 1995c). Some of these mutations appear in clusters
near functionally significant regions of the myosin motor
domain (S1), such as the actin-binding domain, the ATP
catalytic domain, and the LC-binding domain (Fig. 1) (Ray-
ment et al., 1995). A number of mutations have also been
described at the junction between S1 and the S2 (Rayment
et al., 1995). It is becoming increasingly clear that specific
amino acid residues play crucial roles in the ATPase func-
tion of the myosin molecule (reviewed in Rayment et al.,
1996). Studies with the crystal structure of S1 and actin
have led to the proposal that specific residues, loops, -he-
lices, and -sheets may be directly involved in the mecha-
nism of force transduction (reviewed by Vale, 1996; Milli-
gan, 1996). Interestingly, none of the known FHC myosin
mutations occur in proposed critical regions of force pro-
duction, but the proximity of some of the mutations sug-
gests that the motor function of the mutant myosin may be
impaired.
The FHC mutations in this study (Arg249Gln, Arg403Gln,
and Val606Met, highlighted in Fig. 1) were chosen to at-
tempt to identify the biochemical lesion and to determine
whether the lesion correlates with the clinical prognosis.
The Arg249Gln mutation has a moderate phenotype with
respect to incidence and age of sudden death (Watkins et al.,
1992). The Arg403Gln mutation is associated with a high
frequency of sudden death in young adults and heart failure
of adults in their fourth decade (Epstein et al., 1992;
Watkins et al., 1992; Marian et al., 1995a). The Val606Met
mutation is typically associated with a benign form of the
disease, and most patients survive beyond the sixth decade
(Watkins et al., 1992; Marian et al., 1995a). However, in
another study it was reported that 50% of the patients with
this allele in another family died between the ages of 15 and
27 years, suggesting a poor survival rate for Val606Met
mutation in that family (Fananapazir and Epstein, 1994).
These data make it clear that genetic modifiers undoubtedly
exist and affect the clinical outcome of diseased patients.
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However, possible general prognostic implications can be
based on the identified alleles, and it is important to deter-
mine whether it is possible to correlate the clinical pheno-
type with the biochemical defects.
We studied the functional effects of three FHC mutations
by creating mutations in rat cardiac -S1 because of our
interest in studying the FHC disease by using cultured
rodent cardiac myocytes and transgenic rodent models (see
Vikstrom et al., 1996). The dominant myosin isoenzyme of
the left ventricle is -MyHC in rodents and -MyHC in
humans. The amino acid identity between the motor domain
of the rat cardiac -MyHC and human -MyHC is 93%.
None of the FHC mutations that we are studying occur in
sequences that are different, either between - and -MyHC
or between rodent and human MyHC. A transgenic rodent
model of FHC has shown that the presence of the Arg403Gln
mutation in the cardiac -MyHC results in some phenotypic
characteristics of the human Arg403Gln--MyHC FHC dis-
ease (Geisterfer-Lowrance et al., 1996). This mutation, in
the context of an additional mutation in the actin-binding
domain, results in additional phenotypic similarities such as
significant left ventricular hypertrophy (Vikstrom et al.,
1996). Results obtained in transgenic mice expressing FHC
mutations in the  cardiac MyHC suggest that the same
mutation in either  or  MyHC may have similar func-
tional defects.
In the present study, we have expressed and purified rat
-cardiac myosin S1, Arg249Gln-, Arg403Gln-, and
Val606Met-S1 mutants in cultured mammalian cells. We
engineered a histidine tag at the C-terminal of S1 for affinity
purification with a nickel-bound agarose. We report the
Vmax and Km of the actin-activated ATPase activities of the
expressed myosin S1s (a preliminary account was reported
in abstract form in Roopnarine and Leinwand, 1996, 1997).
Our results are consistent with other biochemical studies of
these FHC alleles from an insect cell expression system of
either rat -cardiac HMM (Sweeney et al., 1994) or human
-cardiac HMM (Sata and Ikebe, 1996).
MATERIALS AND METHODS
Reagents
Oligonucleotides for the construction of S1 C-terminus with a histidine
peptide were purchased from Gibco-BRL (Gaithersburg, MD). Ni-NTA
agarose resin and DNA plasmid purification kits were purchased from
Qiagen (Chatsworth, CA). Reagent-grade chemicals were purchased from
Sigma (St. Louis, MO) and Fisher Scientific (Pittsburgh, PA).
Plasmid construction
Rat -MyHC cDNA was previously cloned into the pMT21 expression
vector to yield pMT expression vector (Vikstrom et al., 1993). The FHC
missense mutations were previously introduced into the -MyHC sequence
(Straceski et al., 1994). Cardiac -S1 DNA plasmids were designed by
inserting eight histidines in -S1, -Arg249Gln-, -Arg403Gln-, and
-Val606Met-S1, followed by a stop codon after the 808 a.a. in the
full-length MyHC DNA sequence. The His tag is used to purify the S1
from COS cells by using the Ni-NTA agarose resin. DNA fragments
encoding the C-terminal  His tag were synthesized by polymerase chain
reaction methodology, cloned into PCR-Script vector (Stratagene, La Jolla,
CA), sequenced with a Sequenase reagent kit (USB, Cleveland, OH), and
subcloned into pMT expression vector. Rat VLC1 cDNA was cloned into
pRC-RSV (Invitrogen, Carlsbad, CA), an expression vector with a Rous
sarcoma virus promoter (cloned by Dr. Robert E. Welikson, Cornell
University).
Purification of proteins
The cardiac S1s were expressed in a mammalian cell line from African
green monkey kidney (COS-1 cells), using DEAE-dextran transfection to
introduce the DNA into the cells (Straceski et al., 1994). For each S1
construct, 30 100-mm culture dishes at 50% confluency of COS cells were
transiently transfected and cultured at 37°C for 60 h. Each dish was
transfected with the S1 (12 g) and VLC1 (6 g) plasmids at a ratio of 2:1,
which gave the highest number of cells expressing both S1 and VLC1 in
the same cell.
The COS cells were washed with phosphate-buffered saline solution
(0.17 M NaCl, 6 mM potassium phosphate, 3 mM KCl) to remove serum
proteins, then incubated with lysis solution (50 mM sodium phosphate (pH
8.0), 50 mM NaCl, protease inhibitors (2 g/ml of leupetin, aprotinin,
chymostatin, and pepstatin), 0.1 mM phenylmethylsulfonyl fluoride, 7 mM
-mercaptoethanol (-ME), 0.5% Triton X-100, 1 mM MgCl2, and 1 mM
NaN3) on ice for 30 min. The cells were scraped off the dishes, sonicated
for 10 s, incubated in 5 mM MgATP for 10 min, and then centrifuged at
100,000 rpm to remove cellular debris, nonmuscle myosin filaments, and
nonmuscle actin. The S1 in the supernatant was purified on Ni-NTA resin
by batch purification at 4°C. The supernatant was mixed with nickel-
nitrilo-triacetic acid (Ni-NTA) agarose resin for 2–3 h and centrifuged at
5000  g for 5 min to pellet S1-bound resin. The S1-bound resin was then
washed twice (10 min each) with a high-ionic-strength solution (50 mM
sodium phosphate (pH 7.0), 0.5 M NaCl, 1 mM MgCl2, 0.5 mM -ME),
twice with a low-ionic-strength solution (5 mM sodium phosphate (pH
7.0), 50 mM NaCl, 1 mM MgCl2, 0.5 mM -ME) and eluted with 0.5 M
imidazole (pH 7.0) in the previous buffered solution. The purified S1 was
concentrated with a Amicon Centricon concentrator (mol. wt. 10,000) and
FIGURE 1 The crystal structure of chicken skeletal S1
showing the location of 21 FHC mutations (Rayment et
al., 1995). The mutations are located near the ATP-,
actin-, and light chain-binding region of the myosin head
(discussed in Rayment et al., 1995). The residues in gray
and Arg249, Arg403, and Val606 are those studied in this
paper. The figure was prepared using the program MOL-
SCRIPT, version 2.0 (Kraulis, 1991).
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dialyzed in S1 solution (S1S: 5 mM imidazole (pH 7.0), 1 mM EGTA, 2
mM MgCl2, and 0.1 mM dithiothreitol) at 4°C. The S1 sample was
centrifuged at 14,000  g in an Eppendorf centrifuge for 10 min at 4°C to
remove residual nonmuscle myosin filaments. Rabbit skeletal acetone
powder was prepared as previously described (Thomas et al., 1979) (some
acetone powder was a gift from Dr. David D. Thomas and Dr. John J.
Matta, University of Minnesota, Minneapolis, MN). F-actin was prepared
as described by Thomas et al., (1979) and was dialyzed before the ATPase
assays twice with S1S for 3 h to reduce ATP hydrolysis by actin during the
assays.
Total cellular protein concentration was determined with the Biorad DC
colorimetric assay. The S1 concentration was determined by either Western
blots or slot blots, using an antibody specific to sarcomeric myosin as
described below. The concentration of G-actin was determined spectro-
photometrically from the expression (A290  A320)/E290 (where E290 is the
extinction coefficient (1 mg/ml  0.63) (Thomas et al., 1979). Molar
concentrations were determined using molecular weights of 120,000 for
cardiac chymotryptic S1 and 42,000 for actin (Thomas et al., 1979).
Detection of proteins
Cells grown on glass coverslips were prepared for immunofluorescence as
previously described (Straceski et al., 1994). The following antibodies
were used: sarcomeric MyHC specific monoclonal antibody, F59 (a gift
from Frank Stockdale, Stanford University), or rabbit polyclonal MyHC
antibody (made by Dr. Art S. Rovner, University of Vermont College of
Medicine, Burlington, VT); nonmuscle myosin rabbit polyclonal antibody
(a gift from Dr. Robert Adelstein, National Institutes of Health, Bethesda,
MD); LC specific monoclonal antibody, F310. Immunofluorescence was
detected with a secondary antibody (goat anti-mouse IgG) conjugated to
either fluorescein or rhodamine. Colocalization of S1 and VLC1 was
determined by immunoprecipitation of purified expressed S1 proteins and
cardiac myosin (as a control) with a polyclonal myosin antibody and
protein A (Sigma), as described by L’Ecuyer and Fulton (1993) for Staph
A immunoprecipitation (except that the samples were not radioactive and
magnetic separation was not used).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) (7% acrylamide for myosin and S1 resolution, 12% acrylamide for
LC1 resolution, and 7–12% acrylamide gradient for both S1 and LC1) and
Western blots (Straceski et al., 1994) were used to determine the approx-
imate molecular weights of the myosin fragments. The primary antibodies
described above and secondary antibodies (goat anti-mouse horseradish
peroxidase) were used to visualize the immunoblotted proteins with chemi-
luminescence reagents (Amersham, Arlington Heights, IL). Dog cardiac
chymotryptic S1 (a gift from Dr. Sarkis Margossian, Albany Medical
College, Albany, NY) was used to determine the concentration of purified
S1 on either Western or slot blots. Protein quantitation was done with a
Biorad gel documentation system (Gel Doc 1000) controlled by the Biorad
Molecular Analyst program.
ATPase assays
The actin-activated ATPases were done in S1S (15 M ionic strength) at
25°C in a range of actin concentrations (10–100 M). Reaction aliquots
were removed at 1-, 3-, and 5-min intervals, quenched in 1 M HCl,
centrifuged at 14,000 g, and the supernatants were assayed for inorganic
phosphate from the hydrolysis of ATP, using the malachite green colori-
metric assay as described by Lanzetta et al. (1979). The ATPase activities
were calculated in s1. The Mg-ATPase activity (in the absence of actin)
was subtracted from each actin-activated ATPase. The Vmax (maximum
ATPase rate) and the Km (the actin concentration where the ATPase
activity is half Vmax) were determined from the ordinate and abscissa
intercepts of double-reciprocal plots of 1/ATPase activity (s1) versus
1/[actin] (M). The reported values are the mean  SD of either four (for
- and Arg403Gln-S1) or three (Arg249Gln- and Val606Met-S1) different
preparations. The hydrolysis of ATP by control samples of untransfected
cells was minimal. In some cases contaminating nonmuscle myosin in the
samples resulted in some hydrolysis of ATP, which was subtracted from
the S1 samples before calculation of ATPase values.
RESULTS
The strategy for biochemically characterizing myosin motor
domains was to cotransfect COS cells with expression con-
structs for S1 of the cardiac MyHC and myosin VLC1.
Affinity chromatography was used to isolate the heavy
chain and its associated LC1, and this complex was then
assayed for ATPase activity over a range of actin concen-
trations. This approach depends on obtaining motor do-
mains with an appropriate 1:1 stoichiometry of heavy chains:
light chains. We chose to express amino acids 1–808 of rat
-cardiac MyHC because it was previously shown to bind
to VLC1 with appropriate stoichiometry and to have a
molecular weight similar to that of chymotryptically
cleaved myosin S1 from heart tissue (McNally et al., 1991).
Cotransfection of S1 and VLC1 cDNAs resulted in expres-
sion of both S1 and VLC1 in the same cells (Fig. 2). There
was no obvious difference in the immunofluorescence stain-
ing pattern between wild-type S1 and FHC mutant S1 in the
COS cells (not shown).
The expressed wild-type, FHC-mutant S1’s, and VLC1
had molecular masses similar to that of chymotryptic S1
prepared from heart tissue (120 kDa for S1 and 30 kDa
for VLC1) and migrated as single protein bands on a West-
FIGURE 2 Indirect immunofluo-
rescence detection of S1 and VLC1
cotransfected in COS cells. Antibod-
ies against sarcomeric MyHC (A) and
VLC1 (B) were used to visualize the
expressed proteins. Bar  100 M.
Roopnarine and Leinwand Function of Cardiomyopathy Myosin Mutants 3025
ern blot of a SDS-PAGE (Fig. 3, B and C). The similarity in
the quantity of purified S1 between wild-type and mutant S1
samples suggests that the stability of the protein is not
grossly affected by the FHC mutations, as previously ob-
served for full-length wild-type and FHC mutant MyHC
(Straceski et al., 1994). Quantitation of expressed proteins
showed that a 100-mm culture dish had 1–2 g of ex-
pressed S1 per 2 mg of total cellular protein. The major
reasons for the limited quantity of expressed proteins from
COS cells were that 1) the transfection efficiency of plasmid
DNA was relatively low (40%), 2) the cells were grown
on a monolayer (by necessity) instead of suspension media,
and 3) the expression of high levels of sarcomeric myosin in
nonmuscle cells appears to have some toxicity because
attempts to establish stable cell lines have been unsuccess-
ful. The supernatant from the mixture of COS cell lysate and
Ni-NTA agarose resin did not show any S1, suggesting that
all of the S1 bound to the resin (Fig. 3, A and B, lane 4). The
resin-bound S1 was eluted with 0.5 M imidazole (Fig. 3, A
and B, lane 5). Affinity purification of expressed S1 with
the Ni-NTA agarose resin resulted in similar yields of
wild-type and mutant S1 (not shown). Coomassie blue
staining of the resin-purified samples showed that several
other contaminating proteins were copurified (Fig. 3 A, lane
5). VLC1 is copurified with the resin-purified S1 (Fig. 3 C,
lower panel). Immunoprecipitation with an anti-myosin an-
tibody showed that VLC1 is associated with S1 (Fig. 3 D,
lane 1). Quantitation of the proteins on the Western blot
indicates that the stoichiometry of S1:VLC1 was 1:1, sim-
ilar to that of full-length myosin (Fig. 3 D, lane 2). We
previously showed that there is minimal association be-
tween the nonmuscle light chains and introduced muscle
MyHC in this expression system (Vikstrom et al., 1993).
The main advantage of using S1 rather than the full-
length myosin is that it is soluble under the low-ionic-
strength conditions that are required for optimal S1-actin
binding during the actin-activated ATPases. The Vmax of the
actin-activated ATPase of the expressed -S1 was 11.61 
0.5 s1 (Fig. 4, left), and the Km was 13.28 0.56 M. This
agrees well with ATPase values of tissue purified rat cardiac
S1 that had a Vmax of 14.3 s
1 and a Km of 12.20 M (Lauer
et al., 1989). The Vmax of Arg
249Gln-, Arg403Gln-, and
Val606Met-S1 were 6.82  0.19 s1, 3.29  0.36 s1,
9.93 0.42 s1, respectively (Fig. 4, left). Similarly, the Km
of the FHC mutations were also inhibited, as reflected in an
increase compared to -S1 of 24.5  1.5 M, 45.4  0.5
FIGURE 3 Purification and immunoprecipita-
tion of expressed S1s. (A) Coomassie and (B)
Western blot of 7% SDS-PAGE showing purifi-
cation of S1. Lane 1: High-molecular-weight
markers; lane 2: untransfected COS lysate (COS
control); lane 3: S1 and LC1 transfected COS
lysate; lane 4: supernatant after reacting S1 with
Ni-NTA agarose resin; lane 5: S1 eluted from
resin with 0.5 M imidazole; lane 6: cardiac S1
from dog heart. (C) Western blot of 7–12%
gradient SDS-PAGE of resin-purified samples
showing presence of S1 and LC1. Lane 1: Dog
cardiac S1; lane 2: COS control; lane 3: -S1;
lane 4: -S1; lanes 5 and 6: Arg249Gln-,
Arg403Gln-, and Val606Met-S1, respectively. (D)
Western blot of 7–12% gradient SDS-PAGE of
immunoprecipitated resin-purified expressed
-S1 (lane 1) and cardiac myosin (lane 2)
probed with a sarcomeric myosin antibody and
monoclonal light-chain antibody.
FIGURE 4 Actin-activated ATPases of expressed
S1s. Vmax (left) and Km (right) of actin-activated AT-
Pases of -, Arg249Gln-, Arg403Gln-, and Val606Met-S1
purified from COS cells. The values are the mean  SD
of three or four independent data sets. *For Vmax and Km
values p  0.005 (paired Student-t-test) compared with
wild-type expressed -S1.
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M, and 18.3  1.0 M, for Arg249Gln-, Arg403Gln, and
Val606Met, respectively (Fig. 4, right). When compared to
wild-type -S1, all mutant S1s showed statistically signifi-
cant reductions in Vmax and increases in Km for actin. The
limited quantity of S1s prevented detailed kinetic experi-
ments to determine the specific rate constants that may be
affected by the FHC mutation.
DISCUSSION
Interpretation of data and relationship to
other work
The ATPase activities of the expressed wild-type -S1 (Fig.
3) were similar to S1 purified from rat cardiac tissue (Lauer
et al., 1989). The Vmax of Arg
249Gln-S1 decreased by 1.7-
fold, and the Km increased by 1.85-fold compared with
wild-type -S1, suggesting that an actin-dependent kinetic
rate constant of the ATPase cycle may be affected. Arg249 is
located at the base of the ATP-binding pocket, 29 Å from
the phosphate-binding loop, and is exposed to the surface of
the molecule as it faces the cleft that splits the 50-kDa
domain of S1 (Fig. 5) (Rayment et al., 1995). It is possible
that the Arg249Gln mutation may perturb movements in the
lower 50-kDa domain (highlighted in black in Fig. 5), which
possibly involves a closure of the cleft during transition
from the prehydrolysis state (myosinATP) to a metastable
state (myosinADPPi) (Fisher et al., 1995). It was also
suggested that the movement of the lower domain relative to
the upper domain is directly coupled to a structural change
in the LC domain region of the molecule that may be
responsible for the power stroke during force generation
(Fisher et al., 1995). Alternatively (or additionally), the
proximity of Arg249 to residues that are directly involved in
the mechanism of ATP binding and hydrolysis via charge-
dependent interactions suggests that any charge changes in
Arg249 may result in a negative influence on the overall
myosin ATPase. Arg249 (the equivalent residue in chicken
skeletal S1 is Arg251) is 11.6 Å from cAsp463, which forms
a hydrogen bond with cThr186 (cThr186 is involved in the
coordination of Mg2 ion of the bound ATP) (Smith and
Rayment, 1996). (The corresponding residues in the crystal
structure of chicken skeletal S1 are preceded by “c”, e.g.,
cArg251.) Arg249 is close to cLys248, which may be directly
involved in a salt bridge with cAsp463 during ATP binding
(Fig. 5) (Smith and Rayment, 1996). Our observation that
Arg249Gln decreases the Vmax is consistent with recently
published data (Sata and Ikebe, 1996), in which there was a
twofold decrease in Vmax of human Arg
249Gln--HMM.
However, we observed a 1.85-fold increase in Km, whereas
Sata and Ikebe (1996) reported that Km was unchanged but
the actin motility decreased by 1.6-fold.
A more severe effect on ATPase activity is observed with
the Arg403Gln mutation. The Vmax of Arg
403Gln-S1 de-
creased by 3.5-fold and the Km increased by 3.4-fold com-
pared with -S1, suggesting that the actin-myosin interac-
tion is weakened substantially. Arg403 (equivalent to
cArg405) is at the base of a loop (cArg405-cLys415) that
appears to play an important role during the stereospecific
actin-myosin interaction (Fig. 5) (Milligan, 1996; Rayment
et al., 1993). Molecular docking studies with the crystal
structures of skeletal actin and S1 reveal that the myosin
loop (cArg405-cLys415) is close to the actin residues Pro332-
Glu334 during the actin-myosin interaction (Milligan 1996;
Rayment et al., 1993). It is proposed that the early weakly
binding interaction between myosin and actin involves
charged residues, whereas the later strong-binding interac-
tion involves hydrophobic interactions (Rayment et al.,
1993; Schroder et al., 1993). The Arg403Gln mutation de-
creases the positive charge by one and may be likely to
weaken the actomyosin interaction during force generation.
The importance of Arg403 in the myosin function is also
demonstrated in two other independent mutations of this
residue that cause FHC, Arg403Leu and Arg403Trp (Dausse
et al., 1993; Posen et al., 1995). Individuals with the
Arg403Leu mutation show either a high incidence of sudden
death in young adults or survival into and past the sixth
decade (Dausse et al., 1993). However, the Arg403Trp mu-
tation is quite mild and shows long-term survival of patients
(Dausse et al., 1993; Posen et al., 1995), suggesting that a
change of charge is not solely responsible for the clinical
features of the disease, a notion that has long been discarded
as a prognostic indication for the FHC disease (Vikstrom
and Leinwand, 1996). Our results agree with previously
published reports on the impaired function of expressed
FIGURE 5 Location of FHC mutations in this study. An expanded
region of the ATP- and actin-binding site (from Fig. 1) showing the
location of the FHC mutations of this study. Arg249 faces into the cleft
between the upper and lower 50-kDa domains and is proximal to residues
cLys248 and cAsp463, which appear to form a salt bridge during ATP
binding. Arg403 is at the base of a loop (cArg405-cLys415) that appears to
interact with actin. Val606 appears to be buried in the upper 50-kDa
domain. The figure was prepared using the program MOLSCRIPT, version
2.0.
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Arg403Gln-myosin. The Vmax and Km of Arg
403Gln in the
context of rat -HMM (Sweeney et al., 1994), human
-HMM (Sata and Ikebe, 1996), and Dictyostelium myosin
(Fujita et al., 1997) decreased by 3.4-fold. Myosin from a
soleus muscle biopsy from a patient with the Arg403Gln
mutation showed a threefold decrease in actin motility and
a 1.4-fold decrease in mechanical force of isolated fibers
compared with normal fibers (Cuda et al., 1993a; Lankford
et al., 1996).
The Vmax and Km of Val
606Met-S1 were affected to a
lesser extent compared with the wild-type -S1. The Vmax
decreased by 1.2-fold, and the Km increased by 1.4-fold
compared with wild-type S1, suggesting a slightly de-
creased actomyosin interaction. Val606 lies in the actin-
binding domain and appears to be buried in the upper
50-kDa domain (Fig. 5). Our results differ slightly with a
previous report on actin-activated ATPase of human cardiac
-HMM-Val606Met, which did not demonstrate statistically
significant impairment in actin-activated ATPase (Sata and
Ikebe, 1996). There is also some heterogeneity in data from
patients with this mutation. Force measurements of soleus
muscles from a patient with this mutation were normal in
one report (Thedinga et al., 1996). However, myosin iso-
lated from soleus muscle from a diseased patient in another
family showed that the mutant allele reduced the actin
filament sliding velocity by 2.3-fold (Cuda et al., 1993b).
These differences suggest that a small perturbation in the
motor biochemical function may result in a variable prog-
nosis in patients. It is possible that this difference is due to
differences in the amount of mutant allele in the muscle
fiber or cardiac myocyte. It is also likely that other factors
such as genetic, environmental, and/or exercise influence
the phenotype and onset of the FHC disease.
Our results agree with the moderate prognosis associated
with the Arg249Gln diseased patients (Watkins et al., 1992).
The severe impairment of myosin functional properties by
the Arg403Gln mutation correlates with the poor prognosis
displayed by diseased patients (Watkins et al., 1992; Epstein
et al., 1992; Marian et al., 1992). The mild effect of the
Val606Met mutation on the ATPase activity correlates well
with the benign prognosis for affected patients in two dif-
ferent families (Watkins et al., 1992; Marian et al., 1995a).
Mechanism for FHC disease
The mechanism by which the FHC mutations in sarcomeric
proteins cause hypertrophy and myocyte disarray is still
unknown. It seems increasingly evident that mutations in
sarcomeric proteins are likely to compromise sarcomere
function (in terms of motor function, force production,
and/or protein structure), resulting in hypertrophic cardio-
myopathy. Cardiac hypertrophy can be the result of a num-
ber of stimuli, including exercise, pressure, and volume
overload. It is possible that the mutant sarcomeric protein
(myosin in this report) decreases myocardial contractility of
the myocyte and imposes stress on the cardiac myocytes,
which induces a hypertrophic response. The introduction of
human -Arg403Gln-MyHC into feline cardiac myocytes
resulted in disruption of sarcomeres, which may be due to a
increased protein turnover rate or impaired mutant myosin
binding to actin (Marian et al., 1995b). The latter agrees
with our results of impaired actomyosin interaction of the
Arg403Gln-S1, suggesting that the biochemical defects of
the motor domain may affect myosin filament assembly in
the sarcomere. More recently, it was reported that human
-Arg249Gln- and Arg403Gln-MyHCs assembled normally
into the thick filaments of rat cardiac myocytes, suggesting
that the mutant proteins did not disrupt myofilament assem-
bly (Becker et al., 1997). The differences between these two
reports (Marian et al., 1995b; Becker et al., 1997) may be
due to differences in the cardiac myocytes (feline versus rat)
and/or the amount of mutant protein incorporated into a
sarcomere because different expression vectors with differ-
ent promoters were used in these studies. Interestingly,
intact myofibrillar organization of heart tissue section from
a deceased patient with the Arg403Gln mutation was previ-
ously observed (Vybiral et al., 1992).
CONCLUSIONS
We have shown that missense mutations (Arg249Gln,
Arg403Gln, and Val606Val) in the context of rat -MyHC
impaired the Vmax and Km of the actin-activated myosin
ATPases. Our results suggest that the degree of disruption
of the actomyosin interaction by the FHC mutations may be
directly correlated with the severity of the disease. Future
biochemical analysis of several other FHC mutations will be
needed to establish a definite correlation between the enzy-
matic impairment between different mutants and their clin-
ical phenotype of the heart disease. Our results with the
FHC mutations in the background of rat -MyHC will be
very useful in interpreting studies performed on experimen-
tal laboratory small animal models.
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